Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers

NCT04480333 is registered in ClinicalTrials.gov with Biomed Industries, Inc. as lead sponsor.

NCT NCT04480333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers
Lead sponsor
Biomed Industries, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
September 15, 2020
Completion date
March 31, 2021
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid19, neurodegeneration, neuroinflammatory response, severe acute respiratory infection, severe acute respiratory syndrome, severe acute respiratory syndrome (sars) pneumonia, severe acute respiratory syndrome of upper respiratory tract